Literature DB >> 15696618

Histone H1 as a reporter protein to investigate glycation in bacteria.

Georgi A Stoynev1, Ljuba N Srebreva, Ivan G Ivanov.   

Abstract

Nonenzymatic glycosylation (glycation) of proteins is a multistage chemical process starting as a condensation reaction between reducing sugars and primary amino groups (mainly from the side chains of Lis and Arg) and ending up with formation of complex heterocyclic compounds called advanced glycation end products (AGEs). For a long time, glycation has been attributed to the long-lived eukaryotes (including in humans) only. In a recent study, we showed that glycation also occurs in bacteria. The present study aims to prove that bacterial cytoplasm contains soluble glycating compounds. To this end, Lis/Arg-rich histone H1 isolated from rat liver was treated with deproteinized Escherichia coli cytoplasm through a dialysis membrane. This treatment leads to accumulation of AGEs as well as to a remarkable degradation of the reporter protein on storage at 4 degrees C. Our results indicate also that glycation can be inhibited by acetylsalicylic acid (aspirin), thiamine (vitamin B1), and pyridoxine (vitamin B6).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15696618     DOI: 10.1007/s00284-004-4379-3

Source DB:  PubMed          Journal:  Curr Microbiol        ISSN: 0343-8651            Impact factor:   2.188


  15 in total

Review 1.  Covalent modification reactions are marking steps in protein turnover.

Authors:  E R Stadtman
Journal:  Biochemistry       Date:  1990-07-10       Impact factor: 3.162

2.  Thiamine corrects delayed replication and decreases production of lactate and advanced glycation end-products in bovine retinal and human umbilical vein endothelial cells cultured under high glucose conditions.

Authors:  M La Selva; E Beltramo; F Pagnozzi; E Bena; P A Molinatti; G M Molinatti; M Porta
Journal:  Diabetologia       Date:  1996-11       Impact factor: 10.122

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins.

Authors:  S Reddy; J Bichler; K J Wells-Knecht; S R Thorpe; J W Baynes
Journal:  Biochemistry       Date:  1995-08-29       Impact factor: 3.162

5.  Chelating activity of advanced glycation end-product inhibitors.

Authors:  D L Price; P M Rhett; S R Thorpe; J W Baynes
Journal:  J Biol Chem       Date:  2001-10-24       Impact factor: 5.157

6.  Non-enzymatic glycation of phosphoglucoisomerase.

Authors:  D Zähner; V Liemans; F Malaisse-Lagae; W J Malaisse
Journal:  Diabetes Res       Date:  1989-12

7.  Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis.

Authors:  Timothy J Lyons; Alicia J Jenkins
Journal:  Diabetes Rev (Alex)       Date:  1997

Review 8.  The cellular and molecular mechanisms of diabetic complications.

Authors:  G L King; M Brownlee
Journal:  Endocrinol Metab Clin North Am       Date:  1996-06       Impact factor: 4.741

9.  Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes.

Authors:  P J Beisswenger; Z Makita; T J Curphey; L L Moore; S Jean; T Brinck-Johnsen; R Bucala; H Vlassara
Journal:  Diabetes       Date:  1995-07       Impact factor: 9.461

10.  Glycation and post-translational processing of human interferon-gamma expressed in Escherichia coli.

Authors:  Roumyana Mironova; Toshimitsu Niwa; Rositsa Dimitrova; Maya Boyanova; Ivan Ivanov
Journal:  J Biol Chem       Date:  2003-10-02       Impact factor: 5.157

View more
  1 in total

1.  Response of the bioluminescent bioreporter Pseudomonas fluorescens HK44 to analogs of naphthalene and salicylic acid.

Authors:  J Trögl; G Kuncová; L Kubicová; P Parík; J Hálová; K Demnerová; S Ripp; G S Sayler
Journal:  Folia Microbiol (Praha)       Date:  2007       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.